Zepbound vs Mounjaro: Key Differences Explained

Mounjaro and Zepbound are now the two leading treatments for diabetes and medical weight loss. Both medications contain tirzepatide, a powerful dual-action hormone therapy that targets appetite and blood sugar regulation.

However, even though they both have the same active ingredient, they are marketed and approved for different purposes in the US. If you're in the UK and weighing your options, here’s a breakdown of what sets them apart. Discover more about their mechanisms and what may suit your journey best in this guide.

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it activates two key hormones involved in blood sugar control and appetite regulation. It works by reducing appetite, slowing digestion, and improving insulin sensitivity, which helps lower blood sugar levels.

All these factors make it highly effective for treating type 2 diabetes as well as obesity and weight-related conditions.

Key Differences Explained: Zepbound vs Mounjaro

Even though both Zepbound and Mounjaro contain tirzepatide, there are several key differences to account for.

Mounjaro was approved by the MHRA in the UK for weight management in November 2023, following its approval for type 2 diabetes. On the other hand, Zepbound has only received FDA approval in the United States and is not currently licensed or available in the UK.

The two brands are also positioned differently in the market. Zepbound is marketed specifically as a weight loss medication, while Mounjaro was developed and launched as a treatment for type 2 diabetes and weight loss. Clinical results confirmed its effectiveness in that area.

Accessing Mounjaro in the UK

In the UK, Mounjaro is available through both the NHS and private clinics, though access can vary depending on your circumstances.

NHS access is limited and typically reserved for individuals with a BMI of 35 or higher, or BMI 30+ with weight-related comorbidities such as type 2 diabetes or hypertension. Even if you meet the criteria, wait times can be long, and supply shortages have made consistent access challenging.

For faster and more flexible access, many people turn to private clinics. While this option is self-funded, it often includes ongoing medical support, dose titration, and support packs to help with side effects and lifestyle changes.

Common Side Effects of Mounjaro and Zepbound

Since Mounjaro and Zepbound both contain tirzepatide, they share the same side effect profile. The most common side effects are:

Acid reflux
Bloating
Constipation
Fatigue
Nausea
Reduced appetite
Vomiting

Most side effects are dose-dependent and tend to improve over time, especially with gradual dose increases.

It is important to stay hydrated, eat smaller meals, avoid greasy foods, and get enough rest to help manage discomfort. In rare cases, more serious side effects like pancreatitis, gallbladder issues, or allergic reactions may occur, and these should be discussed with a healthcare provider immediately.

It is important to understand that everyone has different experiences with such medications, and not everyone will experience similar side effects. It’s important to start tirzepatide under medical supervision to monitor how your body responds and adjust the plan if needed.

Choosing between Mounjaro and Zepbound

Who Should Choose Mounjaro?

‍Mounjaro is ideal for adults living with type 2 diabetes who want to improve blood sugar control while also benefiting from weight loss. It’s especially useful for people who need a medication that targets both diabetes and weight management simultaneously.

Mounjaro may also be suitable for those who have tried other GLP-1 receptor agonists like Wegovy but experienced side effects or insufficient results. Additionally, people in the UK who want quicker or private access to tirzepatide-based treatment often turn to Mounjaro, as it is currently more widely available there compared to Zepbound.

Who Should Choose Zepbound?

Zepbound is specifically approved for weight management in adults with obesity or overweight with related health conditions. It’s a good option for individuals primarily focused on weight loss rather than blood sugar control.

Since Zepbound is FDA-approved in the US but not yet available in the UK, it’s mainly an option for those residing in or able to access treatment in the US. People seeking a medication marketed specifically and solely for obesity treatment in the US might prefer Zepbound for its clear positioning as a weight loss drug.

FAQs

Is Zepbound better than Mounjaro?
Zepbound and Mounjaro contain the same ingredient and work the same, but Zepbound is approved specifically for weight loss.

Can I get Zepbound in the UK?
Zepbound is not currently approved or available in the UK, though Mounjaro is.

‍Do Mounjaro and Zepbound work the same?
Yes, both work identically as they use tirzepatide to target appetite and blood sugar.

‍How long does it take for tirzepatide to show results?
Most people start seeing weight loss and blood sugar improvements within 4 to 8 weeks.

‍Are Mounjaro side effects the same as Wegovy?
Yes, both commonly cause nausea, vomiting, and digestive issues, though individual responses can vary.

Key Takeaways:

Both Mounjaro and Zepbound contain tirzepatide, a dual GIP and GLP-1 receptor agonist that helps regulate appetite and blood sugar.
Mounjaro is approved for type 2 diabetes and weight management in the UK. It is available in the UK via the NHS and private clinics.
Zepbound is currently FDA-approved in the US and not yet in the UK.
Mounjaro targets both blood sugar control and weight loss, making it ideal for people with type 2 diabetes who want to lose weight.
Zepbound is designed primarily for weight management in people without diabetes, focusing solely on obesity treatment.
Access to Mounjaro through the NHS requires a BMI of 35+, or 30+ with weight-related conditions, but wait times and supply shortages are common.
Private clinics in the UK offer easier and faster access to Mounjaro, often including dose titration and ongoing medical support.
Common side effects for both medications include nausea, vomiting, acid reflux, bloating, constipation, fatigue, and reduced appetite, which generally improve over time.
Serious side effects are rare but require immediate medical attention; starting treatment under medical supervision is essential.
People who have struggled with other GLP-1 medications like Wegovy may find Mounjaro more tolerable or effective.
Zepbound remains a preferred option in the US for those focusing strictly on weight loss, while Mounjaro serves a dual purpose for diabetes and weight management.
Tirzepatide typically shows results within 4 to 8 weeks, with continued improvement over time.
Both Mounjaro and Zepbound work the same way but differ in regulatory approval, availability, and specific treatment focus.

‍

Disclaimer: At Weightless, we strive to provide accurate, up-to-date health information that is carefully reviewed by medical professionals. However, the content on this blog is intended for general knowledge only and should not be considered a substitute for medical advice, diagnosis, or treatment. Always speak with a qualified healthcare professional about any questions or concerns you may have regarding your health. Information here should not be used to make decisions about your personal care without professional guidance.

‍

Sources:

http://www.ncbi.nlm.nih.gov/books/NBK585056/

https://www.medicines.org.uk/emc/files/pil.15481.pdf

https://www.drugs.com/zepbound.html

‍

You may also be interested in: